Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Official title:
Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The primary objective of this study is to determine the first-cycle maximum tolerated dose (MTD) and recommended Phase II (RP2D) dose of Cabazitaxel when combined with Cisplatin and Follow-Up induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck for three cycles.
The primary study objectives are the following:
- To assess the safety, the maximum tolerated dose (MTD) and the dose limiting toxicity
of cabazitaxel when combined with cisplatin and Follow-Up (FU) induction chemotherapy
in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- To establish the phase II recommended dose of cabazitaxel when combined with cisplatin
and Follow-Up induction in patients with locally advanced squamous cell carcinoma of
the head and neck.
The secondary study objectives, in regards to the combined Cabazitaxel-Platinum Fluorouracil
regimen in patients with newly diagnosed squamous cell carcinoma of the head and neck, are
the following:
- To assess the toxicity profile
- To assess best Overall Response Rate (complete and partial responses) after completion
of 3 cycles of treatment
- To assess Progression Free Survival (PFS) and Overall Survival (OS) after 3 years
Analysis of the secondary variables will be primarily descriptive in nature due to the
small sample size. All results will be considered hypothesis generating to be confirmed
in a future study.
Patient, for whom an informed consent has been obtained and who have met the
inclusion/exclusion criteria after having the screening evaluation performed within a
one-week window, will be assigned to a dose level according to the dose escalation rule
described in the protocol. Treatment consists of an Induction chemotherapy period, which is
the period when the patient will undergo 3 cycles of Cabazitaxel-Platinum Fluorouracil (PF).
The Induction chemotherapy will be followed by Consolidation Therapy, which is 6-7 weeks of
Chemoradiation treatment or Surgery + Recovery time, depending on their primary site and
overall medical condition. Both treatment periods will consist of approximately 16 weeks (9
weeks of Induction and 7 weeks of Consolidation, if Chemoradiation Radiation Therapy (CRT)),
or shorter than 16 weeks, if surgery. After three cycles, the patients will be assessed for
clinical, radiographic, and pathologic response to Cabazitaxel-Platinum Fluorouracil before
beginning Chemoradiation Radiation Therapy or surgery. Patients, who do not complete three
cycles of Cabazitaxel-Platinum Fluorouracil for reasons of toxicity, progressive disease,
choice, or other medical necessity, will be treated with standard Chemoradiation Radiation
Therapy or surgery depending on their primary site and overall medical condition. Once the
Consolidation treatment is completed, the follow-up of patients will be for 3 years.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Recruiting |
NCT06236464 -
Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
|
||
| Terminated |
NCT04659369 -
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
|
Phase 1 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT02572778 -
Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
|
||
| Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
| Terminated |
NCT01488318 -
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT00999700 -
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
|
Phase 3 | |
| Completed |
NCT02565758 -
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02543476 -
SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
|
N/A | |
| Recruiting |
NCT03938012 -
Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
|
||
| Terminated |
NCT02124850 -
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
|
Phase 1 | |
| Active, not recruiting |
NCT03313804 -
Priming Immunotherapy in Advanced Disease With Radiation
|
Phase 2 | |
| Recruiting |
NCT05208762 -
A Study of SGN-PDL1V in Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT04453046 -
Hemopurifier Plus Pembrolizumab in Head and Neck Cancer
|
N/A | |
| Completed |
NCT01758731 -
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
|
Phase 1 | |
| Completed |
NCT02473731 -
A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
|
Phase 1 | |
| Completed |
NCT02022098 -
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
|
N/A | |
| Completed |
NCT01458392 -
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Completed |
NCT02882308 -
Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.
|
Phase 2 |